Faeth Therapeutics, Inc. (FTH) stock
Close on Nov 11, 2026Market cap $344.97MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $344.97M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.99
- Dividend yield
- –
- Free cash flow yield
- -9.82%
Fundamentals
- Net income
- -$195.53M
- EPS, diluted
- -$141.65
- Free cash flow
- -$33.86M
- Book value per share
- $30.65
- Diluted shares
- 6M
Trading
- Next earnings
- Mar 29, 2027 (estimated, before the open)
- Previous close
- $12.92
- Open
- $13.01
- Day's range
- $12.92 – $14.82
- Volume
- 1,362,657
- Average volume (20 days)
- 667,199
- Beta (5 years)
- 1.31
- 52-week range
- $7.45 – $42.14
- RSI (14 days)
- 30.9
- Volatility (1 year)
- 223.6%
- Relative volume
- 3.37×
- WACC
- 11.4%
On 2 of our idea lists: More cash than they're worth, Institutions accumulating
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | FTH | S&P 500 | Difference | FTH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -48.7% | -2.4% | −46.3 pts | ||
| 3 months | -55.5% | -1.2% | −54.3 pts | ||
| Year to date | +25.1% | +12.3% | +12.8 pts | ||
| 1 year | +39.6% | +12.4% | +27.1 pts | ||
| 3 years | -7.3% | +78.8% | −86.1 pts | -2.5% | +21.4% |
| 5 years | -92.3% | +75.2% | −167.5 pts | -40.1% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Faeth Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Results
- Results
- Update
- News
About Faeth Therapeutics
Pharmaceutical Preparations
Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company developing multi-node therapies designed to treat various solid tumors. Its primary clinical program is PIKTOR, an investigational all-oral combination of the selective PI3Kα inhibitor serabelisib and the mTORC1 and mTORC2 inhibitor sapanisertib. By simultaneously suppressing multiple points along the oncogenic PI3K/AKT/mTOR signaling pathway, the company seeks to provide deeper and more durable tumor suppression while limiting acquired resistance mechanisms. The candidate targets patients with endometrial cancer and breast cancer, with potential utility extending across tumors regardless of their direct pathway mutational status.
Company profile, executives and historyFaeth Therapeutics stock: common questions
What is Faeth Therapeutics's stock price?
FTH closed at $13.35 on Nov 11, 2026, up 3.33% on the day. Over the past 52 weeks it traded between $7.45 and $42.14.
What is Faeth Therapeutics's market cap?
Faeth Therapeutics was worth $344.97M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is FTH's P/E ratio?
Faeth Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$141.65), so it has no meaningful P/E ratio.
Does Faeth Therapeutics pay a dividend?
No. Faeth Therapeutics has not paid a cash dividend over the last twelve months.
When does Faeth Therapeutics report earnings next?
Faeth Therapeutics is expected to report Q4 FY2026 results on Mar 29, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has FTH stock performed over the past year?
Including dividends, FTH returned +39.6% over the past year, against +12.4% for the S&P 500.
How many FTH shares are sold short?
3M shares were sold short at the latest FINRA report, 12.76% of the float, or 6.3 days of average trading volume.
Who are Faeth Therapeutics's competitors?
Companies most similar to Faeth Therapeutics by business, industry and size include ACTU, ATOS, FHTX, ORIC, PHIO.
See a number that looks wrong?